Bio-Rad CEO, Norman Schwartz, Discusses Q3 Results and Adjusts 2023 Outlook Amid Biopharma Challenges

  Third-quarter 2023 total net sales were $632.1 million, a decrease of 7.1 percent compared to $680.8 million reported for the third quarter of 20...

October 30, 2023 | Monday | Company results
Marc Casper's Leadership Propels Thermo Fisher to Strong Q3 Performance Amid Market Challenges

Third Quarter 2023 Highlights Third quarter revenue was $10.57 billion, 1% lower versus the same quarter last year. Core organic revenue growth was 1%. ...

October 26, 2023 | Thursday | Company results
Merck CEO Belén Garijo Expresses Confidence in Resilient Growth Model for 2024

Transitional year 2023 managed well so far thanks to resilient business model Medium-term growth targets confirmed Merck expects continued growth also ...

October 25, 2023 | Wednesday | Company results
Novartis Reports Stellar Quarter with Double-Digit Sales Growth, CEO Vas Narasimhan Confident in Strong Mid-Term Outlook

Transformation into a “pure-play” innovative medicines business is complete, with the spin-off of Sandoz; commentary below is on continuing o...

October 24, 2023 | Tuesday | Company results
Roche CEO Thomas Schinecker Reflects on Impressive 2023 Results, Aims for a Bright Future Beyond COVID-19

Group sales grow by 1%1 at constant exchange rates (CER) in the first nine months, showing a strong increase of 7% in the third quarter Excluding COVID-...

October 20, 2023 | Friday | Company results
Sartorius CEO Joachim Kreuzburg Foresees Gradual Recovery in 2023, Eyes Strong Growth in 2024 and Beyond

Sales revenue in constant currencies down 16.4 percent, excluding Covid-19-related business down slightly above 10 percent; underlying EBITDA marg...

October 20, 2023 | Friday | Company results
Novo Nordisk raises sales and operating profit outlook for 2023

In the first nine months of 2023, Novo Nordisk’s sales increased by 33% and operating profit increased by 37% both at CER. Profit and loss (CE...

October 16, 2023 | Monday | News
Avantor CEO Michael Stubblefield Commends Utilization of Avantor Business System to Navigate Tough Market Trends, Expresses Confidence in Long-Term Growth

  "While market trends during the quarter, especially in biopharma, were more challenging than anticipated, we leveraged the Avantor Business System ...

August 29, 2023 | Tuesday | Company results
Agilent's President Mike McMullen Applauds Strong Performance Despite Economic Challenges, Expresses Confidence in Long-Term Growth

Highlights: Reported revenue of $1.67 billion declined 2.7% year-over-year, and decreased 2.3% on a core(1) basis. GAAP net income of $111 millio...

August 18, 2023 | Friday | Company results
"Illumina Reports 8% Sequential Revenue Growth in Q2, NovaSeq X Shipments Exceed Expectations," says Interim CEO Charles Dadswell

Revenue of $1.18 billion for Q2 2023, up 1% from Q2 2022 (up 3% on a constant currency basis) and up 8% from Q1 2023 Shipped 109 NovaSeq X instruments i...

August 10, 2023 | Thursday | Company results
Emergent's 2023 Milestones Bolster America's Preparedness for Public Health Challenges, Securing Financial Resilience, Declares CEO Haywood Miller

Reports Q2 2023 total revenues of $338M, above the prior guidance range, net loss of $261M and adjusted EBITDA of $56M Updates FY 2023 guidance and prov...

August 09, 2023 | Wednesday | Company results
Merck's CEO Belén Garijo Optimistic About 2023 as Healthcare Business Drives Growth

Financial results of Q2 2023 Net sales decrease organically by −1.1% to € 5.3 billion EBITDA pre down organically by −7.0% t...

August 08, 2023 | Tuesday | Company results
Gilead's Remarkable Q2 Performance: 11% Year-Over-Year Growth Fueled by Diverse Therapeutic Portfolio, Positive Regulatory Advances, and Promising Pipeline, Declares CEO Daniel O’Day

Product Sales Excluding Veklury Increased 11% Year-Over-Year to $6.3 billion Biktarvy Sales Increased 17% Year-Over-Year to $3.0 billion Oncology Sales...

August 07, 2023 | Monday | Company results
Bio-Rad's CEO Norman Schwartz Confident Despite Lowered 2023 Expectations Due to Shifting Biotech Market Dynamics

Second-quarter 2023 net sales were $681.1 million, a decrease of 1.4 percent compared to $691.1 million reported for the second quarter of 2022. On a curre...

August 04, 2023 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close